Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zheng, Chaoen
TSL-TCM-QZKL-Ⅲ, NCT06068478: A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis	Recruiting	3	472	RoW	Qingzhu Granules, Qingzhu Granules Placebo	Tasly Pharmaceutical Group Co., Ltd	Gouty Arthritis	10/25	10/25
TQB3702-II-01, NCT06859931: Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)	Not yet recruiting	2	120	RoW	TQB3702 Tablets, TQB3702 Tablets+TQB3702 Placebo, TQB3702 Placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Systemic Lupus Erythematosus	12/26	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zheng, Chaoen
TSL-TCM-QZKL-Ⅲ, NCT06068478: A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis	Recruiting	3	472	RoW	Qingzhu Granules, Qingzhu Granules Placebo	Tasly Pharmaceutical Group Co., Ltd	Gouty Arthritis	10/25	10/25
TQB3702-II-01, NCT06859931: Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)	Not yet recruiting	2	120	RoW	TQB3702 Tablets, TQB3702 Tablets+TQB3702 Placebo, TQB3702 Placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Systemic Lupus Erythematosus	12/26	12/26